Of relevance in ER+/HER2- advanced breast cancer, the therascreen PIK3CA RGQ PCR kit detects PIK3CA mutations to help direct PI3Ka inhibitor treatment (alpelisib)[75,76]. Here, PIK3CA is linked to breast cancer.